Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP) — Stella

Recruiting

Back to Generalized Pustular Psoriasis (GPP) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

China

Peking University People's Hospital (PKUPH), Beijing

Shanghai Huaota Biopharmaceutical Co., Ltd, Shanghai

Key details

Phase

Safety & dosing

Sponsor

Shanghai Huaota Biopharmaceutical Co., Ltd.

Enrollment target

~33 participants

Started

February 2024

Primary completion

February 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated March 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov